Browsing by author "Zvelebil, Marketa Juditha"
Now showing items 1-3 of 3
-
Deconvolution of Buparlisib’s mechanism of action defines specific PI3K and tubulin inhibitors for therapeutic intervention
Bohnacker, T; Prota, AE; Beaufils, F; Burke, JE; Melone, A; et al. (Springer Science and Business Media LLC, 2017-03-09)<jats:title>Abstract</jats:title><jats:p>BKM120 (Buparlisib) is one of the most advanced phosphoinositide 3-kinase (PI3K) inhibitors for the treatment of cancer, but it interferes as an off-target effect with microtubule ... -
GDNF-RET signaling in ER-positive breast cancers is a key determinant of response and resistance to aromatase inhibitors.
Morandi, A; Martin, L-A; Gao, Q; Pancholi, S; Mackay, A; et al. (AMER ASSOC CANCER RESEARCH, 2013-06-15)Most breast cancers at diagnosis are estrogen receptor-positive (ER(+)) and depend on estrogen for growth and survival. Blocking estrogen biosynthesis by aromatase inhibitors has therefore become a first-line endocrine ... -
MoKCa database--mutations of kinases in cancer.
Richardson, CJ; Gao, Q; Mitsopoulous, C; Zvelebil, M; Pearl, LH; et al. (OXFORD UNIV PRESS, 2009-01-01)Members of the protein kinase family are amongst the most commonly mutated genes in human cancer, and both mutated and activated protein kinases have proved to be tractable targets for the development of new anticancer ...